Loxo@Lilly Announces Details of Presentations at the 2022 American Society of Hematology Annual Meeting
The pirtobrutinib oral and poster presentations will provide updated clinical data from the ongoing BRUIN Phase 1/2 study in previously treated chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), Richter transformation, and Waldenström macroglobulinemia. In addition, an analysis of the safety and tolerability of pirtobrutinib monotherapy in patients with relapsed or refractory B-cell malignancies who were intolerant to a prior covalent BTK inhibitor will be presented in a poster presentation. Submitted abstracts on CLL/SLL, Richter transformation, Waldenström macroglobulinemia, and intolerance to prior covalent BTK therapy utilized a
A list of the presentations, along with their viewing details, is shared below.
Presentation Title |
Details |
Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in |
Abstract #229
Clinical and Epidemiological III Date: Presentation Time: Location: Theater C Presenter: |
Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in |
Abstract #347 Leukemia: Clinical and Epidemiological: Targeted Triplet Combinations and Richter's Date: Presentation Time: Location: R06-R09 Presenter: |
Efficacy of Pirtobrutinib in Covalent BTK- |
Abstract #961 Leukemia: Clinical and Epidemiological: Drugs in Development and COVID-19 Date: Presentation Time: Location: 243-245 Presenter: |
Safety and Tolerability of Pirtobrutinib Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the |
Abstract #1797 Poster Session: 642. Chronic Lymphocytic Poster I Date: Time: Location: Hall D Presenter: |
Efficacy of Pirtobrutinib in Covalent BTK- Mantle Cell Lymphoma: Additional Patients and BRUIN Study |
Abstract #4218 Poster Session: 623. Mantle Cell, Follicular, and Clinical and Epidemiological: Poster III Date: Time: Location: Hall D Presenter: |
About Pirtobrutinib (LOXO-305)
Pirtobrutinib is an investigational, highly selective, reversible (non-covalent) Bruton's tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor signaling pathway, which is required for the development, activation and survival of normal white blood cells, known as B-cells, and malignant B-cells. BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström macroglobulinemia. Pirtobrutinib was developed to reversibly bind BTK, deliver consistently high target coverage regardless of BTK turnover rate, and preserve activity in the presence of the C481 acquired resistance mutations. Interested patients and physicians can contact the Loxo@Lilly Physician and Patient BTK Clinical Trial Hotline at 1-855-LOXO-305 or email clinicaltrials@loxooncology.com.
About the BRUIN Phase 1/2 Trial
The BRUIN Phase 1/2 clinical trial is the ongoing first-in-human, global, multi-center evaluation of pirtobrutinib in patients previously treated for mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or other non-Hodgkin lymphomas (NHL).
The trial includes a Phase 1 dose-escalation phase, a Phase 1b combination arm, and a Phase 2 dose-expansion phase. The primary endpoint of the Phase 1/1b study is safety, and secondary endpoints include pharmacokinetics and preliminary efficacy of the drug combinations. The primary endpoint for Phase 2 is overall response rate. Secondary endpoints include duration of response, overall survival, safety, and pharmacokinetics.
About
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about pirtobrutinib for the potential treatment of previously treated chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, Richter transformation, and Waldenström macroglobulinemia and the timeline for future readouts, presentations, and other milestones relating to pirtobrutinib and its clinical trials reflects
©
Refer to:
View original content to download multimedia:https://www.prnewswire.com/news-releases/loxolilly-announces-details-of-presentations-at-the-2022-american-society-of-hematology-annual-meeting-301666931.html
SOURCE